On March 22, 2023 Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, reported their posters were selected for presentation at the Society of Gynecologic Oncology’s (SGO) 2023 Annual Meeting on Women’s Cancer in Tampa, Florida on March 25-28, 2023 and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 in Orlando, Florida on April 14-19, 2023 (Press release, Avenge Bio, MAR 22, 2023, View Source [SID1234629183]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AVB-001, developed in the LOCOcyte platform, consists of proprietary engineered allogeneic human cells. The cells are encapsulated in a pro-inflammatory biomaterial that are delivered to the local tumor environment and generate high, sustained concentrations of human IL-2. The product initiates a robust and durable, local and systemic immune response while avoiding toxicities associated with systemic immunotherapies.
Avenge’s most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers.
Presentation Details:
Conference: Society of Gynecologic Oncology’s (SGO) 2023 Annual Meeting on Women’s Cancer
Location: Tampa Convention Center | Tampa, FL | Exhibit Hall
Session Title: Poster Session 1
Poster Number: 1271
Poster Title: Favorable preclinical efficacy and safety profile of AVB-001, a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first-in-human clinical development
Author: Guillaume Carmona, PhD (Avenge Bio, Inc.)
Date: Sunday, March 26, 2023
Time: 2:00-3:00 PM ET
Conference: American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023
Location: Orange County Convention Center | Orlando, FL | Room W414
Session Type: Methods Workshop (WM007) – Emerging Platforms for Cancer Immunotherapy
Session Title: Developing clinically translatable cytokine factories for cancer immunotherapy
Session Chair & Presenter: Omid Veiseh, PhD (Rice University)
Date: Saturday, April 15, 2023
Time: 12:30-1:00 PM ET
Conference: American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023
Location: Orange County Convention Center | Orlando, FL | Poster Section 46
Session Title: Phase I Clinical Trials in Progress
Poster Number: 10
Abstract Presentation Number: CT122
Poster Title: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube
Author: Shannon N. Westin, MD, MPH (MD Anderson Cancer Center)
Date: Monday, April 17, 2023
Time: 1:30-5:30 PM ET
Conference: American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023
Location: Orange County Convention Center | Orlando, FL | Poster Section 35
Session Title: Late-Breaking Research: Immunology I
Poster Number: 17
Abstract Presentation Number: LB101
Poster Title: Cell-generated IL12 combined with PD-1 inhibition produces local and abscopal immune activation to eradicate metastatic melanoma and pancreatic cancer
Author: Amanda Nash, BS (Rice University)
Date: Monday, April 17, 2023
Time: 9:00 AM-12:30 PM ET
The posters will be available on the Presentations and Publications section of www.avengebio.com following the conference.
About LOCOcyte Platform
Our LOCOcyteTM allogeneic cell-based immunotherapy platform enables potent localized modulation of the immune system which also precipitates a systemic immune response, allowing us to treat previously intractable cancers. The technology leverage three unique advantages:
Potent immune effector molecules are generated by synthetically engineering allogeneic cells creating a ready-to-use therapy,
Therapy is localized in proximity to the primary tumor site and generates innate and adaptive immune response, and
The immunomodulator trains the patient’s immune system generating a robust immune response that seeks and eradicates distal metastasis without systemic toxicity.